ESMO 2022

Conference Coverage

Blood Test Shows Promise for Detecting Cancers Without Approved Screening Tests

Prostate Cancer CTC PSMA Status Could Guide Therapy

Adding Ifosfamide to MAP Provides No Benefit in High-Grade Osteosarcoma

SBRT Does Not Improve Efficacy of Nivo-Ipi in Advanced Merkel Cell Carcinoma

Vaccine-Pembrolizumab Combo Appears Active in HPV+ Advanced Cervical Cancer

Greater PSA Decline Predicts Better ¹⁷⁷Lu-PSMA-617 Outcomes in mCRPC

Real-World Data Support Nivolumab + Ipilimumab for First-Line mRCC Therapy

Immunotherapy and Targeted Therapies in NSCLC: Phase 3 Data From ESMO 2022

Metronomic Chemotherapy Prolongs TTF, PFS in ER+/HER2- Metastatic Breast Cancer

Treatment Advances Have Improved Multiple Myeloma Mortality in the US

Liposomal Irinotecan Improves Upon 5-FU/LV in Refractory Pancreatic Cancer

Donafenib May Be Alternative for Progressive, Advanced RAIR-DTC

¹⁷⁷Lutetium-PSMA-617 After ²²³Radium for mCRPC Safe, Effective

Orelabrutinib Plus R-CHOP Appears Active in Extranodal, Non-GCB DLBCL

Breast Cancer Updates From ESMO 2022

First-Line Pembrolizumab Failed to Improve PFS, OS in Advanced HCC

Update Confirms DFS Benefit With Osimertinib in EGFR-Mutated, Resected NSCLC

¹⁷⁷Lutetium-Octeotrate May Be Practice-Changing for Advanced Pancreatic Neuroendocrine Tumors

Tislelizumab Deemed Noninferior to Sorafenib in Unresectable Hepatocellular Carcinoma

Novel Hormonal Therapies for nmCRPC Underused, Data Show